Drugs & Therapy Perspectives

, Volume 5, Issue 12, pp 1–4 | Cite as

Venlafaxine: another option in major depression

New Drugs and Therapeutics
  • 5 Downloads

Keywords

Fluoxetine Imipramine Venlafaxine Clomipramine Oxybutynin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995 Feb; 49(2): 280–94PubMedCrossRefGoogle Scholar
  2. 2.
    1995 Physicians GenRx. St. Louis, Missouri: Mosby-Year Book, Inc. 1995; 1959–62Google Scholar
  3. 3.
    British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 164–73Google Scholar
  4. 4.
    Reversible MAO-A inhibitors offer better tolerability than older antidepressants. Drug Ther Perspect 1994 Sep 19; 4(6): 12–14Google Scholar
  5. 5.
    American Hospital Formulary Service Drug Information. Bethesda: American Society of Hospital Pharmacists, 1995: 1504Google Scholar
  6. 6.
    Frazer A. Antidepressant drugs. Depression 1994; 2: 1–19CrossRefGoogle Scholar
  7. 7.
    Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023–9PubMedCrossRefGoogle Scholar
  8. 8.
    Sellers EM, Ball SE, Cheung SW, et al. Inhibition by venlafaxine (VF) and other 5HT uptake inhibitors of the polymorphic enzyme CYP2D6 [abstract]. 22nd Annual Meeting of the American College of Neuropsychopharmacology, Honolulu, Dec 13–17, 1993; 163Google Scholar
  9. 9.
    Schweizer E, Weise C, Clary C, et al. Placebo-controlled trial of venlafaxine for the treatment of major depression. J Clin Psychopharmacol 1991; 11: 233–6PubMedCrossRefGoogle Scholar
  10. 10.
    Khan A, Fabre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991; 27: 141–4PubMedGoogle Scholar
  11. 11.
    Mendels J, Johnston R, Mattes J, et al. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993; 29: 169–74PubMedGoogle Scholar
  12. 12.
    Clerc GE, Ruimy P, Verdeau-Paillès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 139–43PubMedCrossRefGoogle Scholar
  13. 13.
    Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14: 322–9PubMedCrossRefGoogle Scholar
  14. 14.
    Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. In pressGoogle Scholar
  15. 15.
    Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995 Mar; 10 Suppl. 2: 15–20PubMedCrossRefGoogle Scholar
  16. 16.
    Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994 Dec 15; 51: 3033–46PubMedGoogle Scholar
  17. 17.
    Effexor. Hosp Formul 1995 Mar; 30: 128Google Scholar
  18. 18.
    Tips for increasing antidepressant prescribing precision. Drug Ther Perspect 1995 Mar 6; 5(4): 10–12Google Scholar

Copyright information

© Adis International Limited 1995

Personalised recommendations